GlassScriptPhysician profile
Waqaar Ahmed Arshad
NPI 1447812540
$611.01
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $61.45 · 2021: $370 · 2022: $29.26.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $249.86 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $141.78 | 2019-2022 | |
| Pfizer INC. | $42.27 | 2020-2021 | |
| Edwards Lifesciences Corporation | $29.20 | 2020-2021 | |
| Vapotherm INC | $24.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.57 | 2021 | |
| La Jolla Pharmaceutical Company | $21.95 | 2021 | |
| Gilead Sciences, INC. | $21.21 | 2021 | |
| Amgen INC. | $17.55 | 2020 | |
| Fisher & Paykel Healthcare INC | $14.84 | 2022 | |
| Allergan, INC. | $12.64 | 2019 | |
| Abbvie INC. | $11.62 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waqaar Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.